Accepted Manuscript

Design and synthesis of some novel 4-Chloro-N-(4-(1-(2-(2-

cyanoacetyl)hydrazono)ethyl)phenyl) benzenesulfonamide derivatives as anticancer
and radiosensitizing agents

Mostafa M. Ghorab, Fatma A. Ragab, Helmy I. Heiba, Aiten M. Soliman

PII: S0223-5234(16)30291-4
DOI: 10.1016/j.ejmech.2016.04.009
Reference: EJMECH 8524

To appear in: European Journal of Medicinal Chemistry

Received Date: 29 February 2016

Revised Date: 30 March 2016
Accepted Date: 4 April 2016

Please cite this article as: M.M. Ghorab, F.A. Ragab, H.I. Heiba, A.M. Soliman, Design and synthesis
of some novel 4-Chloro-N-(4-(1-(2-(2-cyanoacetyl)hydrazono)ethyl)phenyl) benzenesulfonamide
derivatives as anticancer and radiosensitizing agents, European Journal of Medicinal Chemistry (2016),
doi: 10.1016/j.ejmech.2016.04.009.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
 ACCEPTED MANUSCRIPT
Graphical Abstract

Title: Design and synthesis of some novel 4-Chloro-N-(4-(1-(2-(2-cyanoacetyl)

hydrazono)ethyl)phenyl)benzenesulfonamide derivatives as anticancer and
radiosensitizing agents.

PT
Novel series of sulfonamide derivatives bearing a biologically active hydrazone or
pyridone moiety were synthesized. The most potent compounds in this study 4, 10
and 12 were evaluated for their radiosensitizing activity.

RI
U SC
AN
M
D
TE
C EP
AC
 ACCEPTED MANUSCRIPT
Design and synthesis of some novel 4-Chloro-N-(4-(1-(2-(2-
cyanoacetyl)hydrazono)ethyl)phenyl) benzenesulfonamide
derivatives as anticancer and radiosensitizing agents.

Mostafa M. Ghoraba,b*, Fatma A. Ragabc, Helmy I. Heibaa, Aiten M. Solimana.

a
Department of Drug Radiation Research, National Center for Radiation Research and Technology,
Nasr City, Cairo, Egypt.

PT
b
Department of Pharmacognosy, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh
11451, Saudi Arabia.
c
Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmacy, Cairo University.

RI
*Correspondence author; E-Mail: mmsghorab@yahoo.com ; Tel.: +966-53-4292-860; Fax: +966-01-
4670-560.

SC
Abstract A novel series of sulfonamide derivatives 4-21 have been synthesized
starting from the strategic starting material (E)-4-Chloro-N-(4-(1-(2-(2-
cyanoacetyl)hydrazono)ethyl)phenyl) benzenesulfonamide 4. Two series of

U
hydrazone 5-9, and pyridone 10-21 derivatives bearing a sulfonamide moiety were obtained.
All the newly synthesized compounds were evaluated for their in vitro cytotoxic activity
AN
against human liver cancer cell line (HepG2). Compounds 4-6, 8, 9, 10-14 and 16-18 showed
higher activity compared to doxorubicin as a positive control. The radiosensitizing ability of
the most promising compounds 4, 10 and 12 was studied which showed an increase in the cell
killing effect of γ-radiation after combination with these derivatives. The molecular design
M

was performed to predict the binding mode of the most promising compounds 4, 10 and 12
with the active site of hCA IX, that showed appropriate fitting with the relevant amino
D

acids in the binding pocket on the basis of standard bond lengths, angles, S score and
E conformation data.
TE

Keywords: Sulfonamide, anticancer, radiosensitizers.

EP

1. Introduction

Based on the World Health Organization (WHO) report, cancer is one of the
C

most prominent causes of morbidity and mortality worldwide [1]. The discovery of
novel small molecules with potential usefulness as potent and selective anticancer
AC

agents is still a major challenge to medicinal chemistry researchers [2]. Current

antitumor chemotherapy suffers from two major limitations, the first being the lack of
selectivity of conventional chemotherapeutic agents for cancer tissues, causing
unwanted side effects. The second is the acquisition of multiple-drug resistance by
cancer cells, rendering them unresponsive to conventional chemotherapeutic agents
[3,4].
Sulfonamides were found to posses many types of biologically interesting
activities including anticancer activity [5-7]. There are a variety of mechanisms
describing the antitumor action of sulfonamides, such as cell cycle arrest in the G1
phase, disruption of microtubules and angiogenesis inhibition. The most prominent
mechanism is the inhibition of carbonic anhydrase isozymes (CAs) [8]. Aromatic or

1
 ACCEPTED MANUSCRIPT
heteroaromatic sulfonamides have been shown to reverse the effect of tumor
acidification, consequently they inhibit the growth of cancer cells and suppress tumor
invasion mediated by carbonic anhydrases [9, 10]. CA inhibitors compromise the
survival of tumor cells due to perturbed pH control, or can be used in combination
with other conventional chemotherapeutics as doxorubicin to improve their uptake
and efficacy due to modulated pH gradient. [11-18].
On the other hand, Literature survey has revealed that hydrazone moiety has
significant biological activity as antibacterial, antimicrobial [19] antioxidant [20],

PT
HIV-1 integrase inhibitor [21] and anticancer [22-25] due to their ability to inhibit
dihydrofolate reductase enzyme [26], also act as EGFR dimerization inhibitor [27]
and c-Met kinase inhibitor, with pronounced selectivity towards T-lymphoblastic
leukaemia cells, HT-29 colon cancer cell line and HepG2 Liver cancer cell line[28].

RI
Also, pyridones have many biological activities as antifungal [29],
antibacterial [30], anti-inflammatory [31], antiviral [32], antimalarial [33], oxytocin

SC
antagonist [34], Liver-targeting SCD1 inhibitor which is a crucial factor in lipid
metabolism and body weight control [35], and anticancer [36] through many
mechanisms as inhibition of FGFR and other members of the tyrosine kinase family,

U
including VEGFR, c-Kit and Flt3. Met and TAM family kinases inhibitor, through
Axl inhibition [37].
AN
.

As a recent approach for designing new compounds is the development of

hybrid molecules through the combination of different pharmacophores that leads to
M

compounds with interesting biological profiles [38, 39]. Following this approach and
as a part of an ongoing effort to find alternate chemotherapeutic agents for
hepatocellular carcinoma [40-43], we herein, are reporting the design and synthesis of
D

some novel sulfonamide derivatives bearing biologically active hydrazone and

pyridone moeities for evaluation as anticancer and radiosensitizing agents on human
TE

liver tumor cell line (HepG2).

2. Results and Discussion

EP

2.1. Chemistry

Schemes 1 and 2 illustrated the synthetic strategies utilized for the synthesis of
C

the target compounds 4-21 from the starting material N-(4-acetylphenyl)-4-

chlorobenzenesulfonamide 3 [44]. Reaction of 3 with the nitrogen nucleophile 2-
AC

cyanoacetohydrazide yielded the strategic starting material (E)-4-chloro-N-(4-(1-(2-

(2-cyanoacetyl)hydrazono)ethyl)phenyl)benzenesulfonamide 4 in a good yield
(scheme 1). IR spectrum of compound 4 revealed characteristic strong intensity bands
at 3282 and 3202 and 2185 cm-1 for the introduced 2NH and C≡N groups,
respectively, confirming the formation of cyanoacetyl hydrazono derivative. 1H-NMR
spectrum displayed an up-field singlet at 4.16 ppm for the introduced CH2 group and
a downfield shifted singlet appearing at 10.52 ppm due to the addition of NH group,
which is exchangeable with D2O. 13C-NMR exhibited a new up-field signal at 25.3
ppm for the CH2 group and a new signal at 119.9 ppm assigned to the C≡N group.
Reaction of 4 with dimethylformamide dimethylacetal (DMF-DMA) in dry xylene
yielded the corresponding acrylohydrazide derivative 5 through the formation of

2
 ACCEPTED MANUSCRIPT
carbanion (scheme 1). 1H-NMR spectrum of 5 displayed an up-field singlet at 3.19
ppm for the addition of N(CH3)2 group and a downfield shifted singlet appearing at
7.80 ppm due to the introduced CH group. Also, 1H-NMR spectrum showed the
disappearance of the singlet corresponding to the CH2 group of 4. 13C-NMR exhibited
a new up-field signal at 66.8 ppm for the introduced N(CH3)2 group and a down-field
signal at 154.0 ppm assigned to the CH group. Reaction of 4 with triethylorthoformate
in acetic anhydride yielded the corresponding acrylohydrazide derivative 6 (scheme
1). 1H-NMR spectrum of 6 displayed up-field triplet and quartet at 1.30 and 4.10 ppm
for the addition of CH3 and CH2 groups, respectively. A downfield shifted singlet

PT
appearing at 8.37 ppm assigned to the CH group. Also, 1H-NMR spectrum showed the
disappearance of the singlet corresponding to the CH2 group of 4. 13C-NMR exhibited
two new up-field signals at 25.5 and 79.8 ppm for the introduced CH3 and CH2

RI
groups, respectively. A down-field signal at 163.2 ppm for the addition of CH group.
Reaction of 4 with CS2 in N,N-dimethylformamide containing KOH followed by
acidification afforded the propanedithioic acid derivative 8 via the non-isolated

SC
intermediate potassium dithiolate 7, while treatment of 7 with 2 moles of methyl
iodide afforded the acrylohydrazide derivative 9 (scheme 1). IR spectrum of 8
revealed two bands at 2300 and 1310 cm-1 corresponding to the SH and C꞊S groups,
respectively. 1H-NMR spectrum displayed an up-field singlet at 2.14 ppm for the SH

U
group and another singlet at 4.16 ppm assigned to the CH group. 13C-NMR exhibited
a new down-field signal at 196.9 ppm for the introduction of C꞊S group. 1H-NMR
AN
spectrum of 9 displayed an up-field singlet at 2.49 ppm for the 2(S-CH3) groups.
Also, 1H-NMR spectrum showed the disappearance of the singlet corresponding to the
CH2 group of 4. 13C-NMR exhibited a new up-field signal at 28.3 for the 2(S-CH3)
M

groups and a down-field signal at 176.9 ppm for the addition of S-C-S group.

The synthesis of the target pyridone derivatives 10-21 involved reaction of 4

D

with different ethyl α-cyanocinnamate derivatives in ethanol through nucleophilic

substitution followed by intramolecular cyclization to yield the corresponding
pyridone derivatives 10-21 (scheme 2). IR spectra confirmed the assigned structures
TE

by the presence of significant bands for NH2, C≡N, 2 C=O and SO2 at their specified
regions. 1H-NMR spectra of 10-21 showed downfield shifted singlet at (10.66-10.74)
ppm due to the introduction of NH2 group which is exchangeable with D2O. Also, 1H-
EP

NMR spectra showed the disappearance of the singlet corresponding to the CH2 group
of 4. 13C-NMR spectra of 10-21 exhibited two new up-field signals for the CH3 and
CH2 groups, another C-C=N signal responsible for the ring closure and a downfield
C

signal assigned to the C=O ester group at their specified regions.

AC

3
 ACCEPTED MANUSCRIPT

PT
RI
U SC
AN
M
D
TE
EP
C
AC

4
 ACCEPTED MANUSCRIPT

PT
RI
U SC
AN
M
D

2.2. In-vitro anticancer evaluation against human tumor liver cancer

TE

(HepG2)
EP

A closure look to the structure activity relationship (SAR) of the results in

Table 1, it was found that the cyanoacetohydrazone derivative 4 showed the most
potent activity (IC50 ꞊ 8 µM) i.e. four times higher in activity than doxorubicin. The
formation of hydrazone derivatives 5, 6, 8 and 9 (IC50 ꞊ 19.4, 16.8, 17.5 and 19.4 µM,
C

respectively) still gave potent derivatives compared to the reference drug. The most
active derivative was the ethoxy derivative 6 (IC50 ꞊ 16.8 µM).
AC

Concerning the pyridone derivatives the 4- aryl substituent markedly affected

the cytotoxic activity. Where, compounds 10, 12, 13, 14 and 16 (IC50 ꞊ 10.3, 8.38,
10.7, 11.4 and 11.4 µM, respectively) showed better activity compared to the
reference drug. The most active derivative was 12 with p-tolyl substituent (IC50 ꞊ 8.38
µM). On the other hand compounds 19 and 20 (IC50 ꞊ 37 and 29.7 µM) showed
relatively equipotent activity compared to that of the reference drug, due to the
introduction of m-nitrophenyl and piperonyl substituents to the pyridone ring. While
compounds 15 and 21 with p-methoxyphenyl and p-nitrophenyl substituents showed
poor activity compared to that of doxorubicin.

5
 ACCEPTED MANUSCRIPT
Table 1: In vitro anticancer screening of the synthesized compounds against human
liver cell line (HepG2).
Compound concentration (µM)
Cpd. No. 12.5 (µM) 25 (µM) 50 (µM) 100 (µM) IC 50 (µM)
a
Surviving fraction (mean ± SE)
DOX. 0.551 ± 0.026 0.480 ± 0.003 0.139 ± 0.005 0.130 ± 0.016 32
4 0.180 ± 0.056 0.159 ± 0.025 0.078 ± 0.008 0.064 ± 0.044 8
5 0.642 ± 0.041 0.386 ± 0.049 0.311 ± 0.017 0.281 ± 0.022 19.4

PT
6 0.556 ± 0.020 0.406 ± 0.029 0.228 ±0.014 0.222 ± 0.021 16.8
8 0.542 ± 0.018 0.448 ± 0.044 0.387 ± 0.021 0.248 ± 0.008 17.5
9 0.579 ± 0.030 0.440 ± 0.014 0.329 ± 0.027 0.266 ± 0.010 19.4

RI
10 0.413 ± 0.032 0.367 ± 0.014 0.370 ± 0.016 0.342 ± 0.006 10.3
11 0.617 ± 0.025 0.287 ± 0.008 0.212 ± 0.015 0.179 ± 0.007 16.8

SC
12 0.264 ± 0.021 0.250 ± 0.022 0.214 ± 0.028 0.107 ± 0.015 8.38
13 0.414 ± 0.027 0.336 ± 0.032 0.275 ± 0.020 0.114 ± 0.009 10.7
14 0.489 ± 0.009 0.129 ± 0.006 0.105 ± 0.018 0.087 ± 0.011 11.4

U
15 0.651 ± 0.025 0.637 ± 0.098 0.613 ±0.003 0.147 ± 0.034 61.7
16 0.488± 0.023 0.545± 0.033 0.342 ± 0.010 0.192 ± 0.015 11.4
AN
17 0.555 ± 0.032 0.463 ± 0.014 0.394 ± 0.016 0.314 ± 0.006 20.2
18 0.653 ± 0.015 0.432 ± 0.006 0.396 ± 0.010 0.196 ± 0.006 21
19 0.691 ± 0.023 0.606 ± 0.020 0.373 ± 0.018 0.134 ± 0.015 37
M

20 0.661 ± 0.027 0.524 ± 0.032 0.381 ± 0.020 0.298 ± 0.009 29.7

21 0.713 ± 0.009 0.586 ± 0.006 0.483 ± 0.018 0.212 ± 0.011 41.1
D

a
Each value is the mean of three experiments ± standard error.
TE

2.3. Radiosensitizing evaluation

The ability of the most active compounds 4, 10 and 12 to enhance the cell
killing effect of ɤ-irradiation was studied. From the results obtained in table 2,
EP

compound 4 showed in vitro cytotoxic activity with IC50 value of 8 µM, when the
cells were subjected to different concentrations of the compound alone. While when
the cells were subjected to the same concentrations of compound 4, and irradiated
C

with a single dose of ɤ-radiation at a dose level of 8 Gy, the IC50 value was
AC

synergistically decreased to 6.5 µM. Similarly, compound 10 showed IC50 value of

10.3 µM when tested alone. The IC50 value was decreased to 8.8 µM, when the cells
were treated with compound 10 in combination with ɤ-radiation. Also, compound 12
showed IC50 value of 8.38 µM when used alone. The IC50 value was decreased to 7.3
µM, when the cells were treated with compound 12 in combination with ɤ-radiation.
The results proved the ability of the synthesized compounds to sensitize cancer cells
to the lethal effect of ionizing radiation in order to decrease the dose of the drug and
decrease its toxicity. The change in IC50 (µM) for compounds 4, 10 and 12 against
HepG2 after irradiation is illustrated in table 2.

6
 ACCEPTED MANUSCRIPT
Table 2: In vitro anticancer screening of compounds 4, 10 and 12 against human liver
cell line (HepG2) in combination with radiation.
Compound concentration (µM) +
Cpd. Irradiated irradiation (8 Gy) IC 50
Control a
No. (8 Gy) Surviving fraction (mean ± SE) (µM)
12.5 25 50 100
0.26 ± 0.25± 0.12 ± 0.11±
4 1.000 0.927 ±0.02* 6.5
0.08* 0.01* 0.01* 0.01*

PT
0.32 ± 0.22± 0.10 ± 0.10 ±
10 1.000 0.927 ±0.02* 8.8
0.01* 0.02* 0.01* 0.01*
0.18 ± 0.15 ± 0.12± 0.11 ±

RI
12 1.000 0.927 ±0.02* 7.3
0.02* 0.01* 0.01* 0.01*
a:
Each value is the mean of three values ± Standard Error

SC
*
: Significant difference from control group at p<0.001

2.4. Molecular modeling and docking study

U
Carbonic anhydrases (CA, EC 4.2.1.1) represent a family of Zn based
AN
metalloenzymes that catalyzes the interconversion between carbon dioxide and
bicarbonate with generation of protons. Thus inhibition of which has proven
beneficial in the field of selective cancer therapy [11].
M

Crystallographic data revealed that CA IX, which is a membrane-associated α-

CA, is comprised of a dimer each monomer of which consists of 10-stranded
D

antiparallel sheets forming the core of the molecule with an intramolecular disulfide
bond between Cys23 and Cys203 [45, 46]. CA IX active site contains a Zn(II) in
TE

coordination with His 94, 96, 119 and a water molecule. The essential binding pocket
amino acids are the proton shuttle residues involved in the binding with inhibitors [44,
45]. Thus, Leu91, Val121, Val131, Leu135, Leu141, Val143, Leu198 and Pro202
define the hydrophobic region of the active site, whereas Arg58, Arg60, Asn62,
EP

His64, Ser65, Gln67, Thr69 and Gln92 identify the hydrophilic one.

In an attempt to rationalize the cytotoxic activity profile exhibited by the

C

synthesized compounds, a molecular modeling study was carried out. A

conformational search using an implicit solvent model was accomplished for the
AC

prepared compounds; this was followed by refinement of the geometry of local

minima through a quantum-mechanical (QM) method. Subsequently, flexible docking
of the compounds was performed in the crystallographic structure of the CA IX co-
crystallized with a sulfonamide native ligand obtained from the Protein DataBank
(PDB ID: 4BCW) [46] to assess the plausible ability of the new sulfonamide
derivatives to bind in the active pocket of CA IX as a potential molecular target. The
poses obtained for our sulfonamides were found to bind in a co-crystallized ligand-
like fashion with CA IX (Figures 1–5).

Initially, docking validation was performed to assert the ability of the docking
protocol to recognize the active site and reproduce the docking results. Figure 1
displays the superposition of the co-crystallized ligand and the re-docked ligand

7
 ACCEPTED MANUSCRIPT
which was found to bind at the same position and with the same manner (S= -14.04
Kcal mol-1).

PT
RI
U SC
AN
M
D
TE

Figure 1. Docking validation for the re-docked ligand (red) compared to the co-
crystallized ligand (blue) in the active site of CA IX (S=-14.04 Kcal mol-1).
EP

Docking of all the synthesized compounds was performed and herein the
findings obtained for the three most active compounds in this study, sulfonamide
C

derivatives 4 (Figures 2 and 3) and 10 (Figures 4), 12 (Figure 5) were presented. 3D

ligand interaction of the sulfonamide derivative 4 (Figure 2) shows that the compound
AC

binds in the same site as the co-crystallized ligand with a binding energy reported by
an S score of -10.92 Kcal mol-1. On the other hand, the 2D ligand interaction (Figure
3) demonstrates that the compound binds with the amino acids of the active site
Thr200, Thr199, His119, His96 and His94 as well as the Zn atom through a network
of hydrogen bonds (2.03–3.08Å). Regarding the docking results of compound 10, the
2D ligand interaction simulation (Figures 4) showed that 10 binds in the same fashion
to the co-crystallized ligand displaying a set of hydrogen bonds with the active pocket
amino acids Thr200, Thr199, His119, His96, His94 and Gln92 as well as water and
Zn interactions leading to an overall binding energy of =-10.49 Kcal mol-1. Regarding
the docking results of compound 12, the 2D ligand interaction simulation (Figures 5)
showed that 12 binds in the same fashion to the co-crystallized ligand displaying a set

8
 ACCEPTED MANUSCRIPT
of hydrogen bonds with the active pocket amino acids Thr199, His119 and His94 as
well as Zn interactions leading to an overall binding energy of =-10.99 Kcal mol-1.

These observed favorable interactions between CA IX and the new

sulfonamide derivatives might, at least in part, explain the observed cytotoxic activity
of this series of compounds. Further investigations to explore more the plausible
mechanism of action of these derivatives are underway.

PT
RI
U SC
AN
M
D
TE

Figure 2. 3D Docking of sulfonamide derivative 4 (red) (S=-10.92 Kcal mol-1)

EP

compared to the co-crystallized ligand (blue) in the active site of CA IX.

C
AC

9
 ACCEPTED MANUSCRIPT

PT
RI
SC
Figure 3. 2D ligand interaction of sulfonamide derivative 4 with active site amino
acids of CA IX.

U
AN
M
D
TE
C EP

Figure 4. 2D ligand interaction of sulfonamide derivative 10 with active site amino

AC

acids of CA IX.

10
 ACCEPTED MANUSCRIPT

PT
RI
U SC
Figure 5. 2D ligand interaction of sulfonamide derivative 12 with active site amino
acids of CA IX.
AN
3. Conclusion
M

In summary, a novel series of sulfonamide derivatives were synthesized. The

prepared compounds were designed and synthesized as potential carbonic anhydrase
inhibitors (CAIs) and evaluated for their potential anticancer activity against human
D

liver cancer cell line (HepG2). Compounds 4-6, 8-14, 16 and 18 were found to be
more potent than doxorubicin. From the SAR, we may conclude that the introduction
TE

of cyanoacetohydrazone derivative is associated with enhanced anticancer activity

and gave the most potent compound in this study 4 (IC50= 8.0 µM). Combination of
sulfonamide with pyridone moiety with different substitution in compound 12 and 10
also showed potent activity (IC50= 8.38 and 10.3 µM). This study may provide
EP

valuable information for further investigations as anticancer agents. Moreover, the

most active compounds showed interesting radiosensitizing activity when evaluated
for their in-vitro anticancer activity in combination with γ-radiation.
C

4. Experimental
AC

4.1. Chemistry

Melting points were uncorrected and were taken in an open capillary tube on a
Stuart melting point apparatus (Stuart Scientific, Redhill, UK). The IR spectra of the
compounds were recorded on ABB Bomem FT-IR spectrometer MB 104 with KBr
pellets. 1H-NMR and 13C-NMR spectra were recorded using a Bruker 300 and 400
NMR spectrometers operating at 300 and 400 MHz, respectively. Mass spectra were
run on Shimadzu. GCMS/ QP 5050 mass spectrometer (Shimadzu, Tokyo, Japan).
Microanalyses were obtained with an Elemental analyses system GmbH VarioEL
V300 element analyzer which were found within the limit of 0.4 % of theoretical
values for all the synthesized compounds. The purity of the compounds was checked

11
 ACCEPTED MANUSCRIPT
by thin layer chromatography (TLC) with precoated Aluminum sheets Silica gel
Merck 60 F254 and were visualized by UV lamp (Merck, Damstadt, Germany). The
developing solvent system was chloroform/methanol (7:3) and the spots were
visualized in UV chamber. IR, 1H-NMR, 13C-NMR, mass spectra and elemental
analysis were consistent with the assigned structures. IR spectra were performed at
National Center for Radiation Research and Technology, Atomic Energy Authority.
While 1H-NMR and 13C-NMR spectra were performed at Chemical Warfare
department, Ministry of Defense. Mass spectra were done at the Microanalytical
Laboratories of Al-Azhar University. Elemental analysis were performed at the

PT
Microanalytical Laboratories of the Faculty of Science, Cairo University. 4-
Clorobenzene sulfonyl chloride and 4- aminoacetophenon were purchased from
Sigma-Aldrich.

RI
4.1.1.(E)-4-Chloro-N-(4-(1-(2-(2-cyanoacetyl)hydrazono)ethyl)phenyl)

SC
benzenesulfonamide (4).

A mixture of 2–cyanoacetohydrazide (0.99 g, 0.01 mol) and N-(4-acetylphenyl)-4-

chlorobenzenesulfonamide 3 (3.09 g, 0.01 mol) [44] was refluxed in 1,4-dioxane (15

U
mL) for 3h. The reaction mixture was poured onto ice/ water and the solid obtained
was crystallized from ethanol to give 4. Yield, 64 %; m.p. 210-212 ºC. IR(KBr,cm-1):
AN
3282, 3202 (2NH), 3052 (CH arom.), 2922, 2830 (CH aliph.), 2185 (C≡N), 1720
(C=O), 1610 (C=N), 1347, 1162 (SO2), 754 (C-Cl). 1H-NMR (DMSO-d6): 2.15 [s,
3H, CH3], 4.16 [s, 2H, CH2], 7.10, 7.80 [2d, 4H, Ar-H AB system, J= 6.8 Hz], 7.61 [s,
M

1H, SO2NH exchangeable with D2O], 7.64, 7.76 [2d, 4H, Ar-H AB system, J= 6.8
Hz], 10.52 [s, 1H, NH exchangeable with D2O]. 13C-NMR (DMSO-d6): 22.0 (CH3),
D

25.3 (CH2), 119.9 (C≡N), 127.7, 127.7, 127.8, 129.0, 129.0, 129.9, 129.9, 130.0,
130.0, 134.5, 138.4, 138.7 (C-phenyl), 154.0 (C=N), 159.0 (C꞊O). MS m/z (%): 390.8
TE

(M+) (1.4), 392.5 (0.4), 90.7 (100). Anal. Calcd. For C17H15ClN4O3S (390.84): C,
52.24; H, 3.87; N, 14.33 Found: C, 52.38; H, 3.90; N, 14.50.
EP

4.1.2.4-Chloro-N-(4-((E)-1-(2-((E)-2-cyano-3-(dimethylamino)acryloyl)
hydrazono)ethyl)phenyl)benzenesulfonamide (5)

A mixture of 4 (3.9 g, 0.01 mol) and dimethylformamide-dimethylacetal (DMF-

C

DMA) (1.19 g, 0.01 mol), in dry xylene (15 ml) was refluxed for 5h. The reaction
AC

mixture was cooled, and the solid obtained was crystallized from ethanol to give 5.
Yield, 56%; m.p. 240-242 ºC. IR (KBr, cm-1): 3385, 3321 (2NH), 3097 (CH arom.),
2922, 2859 (CH aliph.), 2185 (C≡N), 1710 (C=O), 1602 (C=N), 1373, 1180 (SO2),
755 (C-Cl). 1H-NMR (DMSO-d6)δ: 2.13 [s, 3H, CH3], 3.19 [s, 6H, N(CH3)2], 7.07-
7.76 [m, 8H, Ar-H], 7.60 [s, 1H, SO2NH exchangeable with D2O], 7.80 [s, 1H, CH],
10.51 [s, 1H, NH exchangeable with D2O]. 13C-NMR (DMSO-d6): 23.5 (CH3), 66.8,
66.8 (N(CH3)2), 119.9 (C-CN), 120.0 (C≡N), 127.7, 127.7, 129.0, 129.0, 129.0, 129.9,
129.9, 134.5 ,134.5, 138.3, 138.3, 138.5 (C-phenyl), 138.7 (C=N), 154.0 (CH), 159.0
(C꞊O). MS m/z (%): 445.8 (M+) (15.4), 447.7 (5.8), 63.6 (100). Anal. Calcd. For
C20H20ClN5O3S (445.92): C, 53.87; H, 4.52; N, 15.71; Found: C, 54.01; H, 4.73; N,
15.82.

12
 ACCEPTED MANUSCRIPT
4.1.3.4-Chloro-N-(4-((E)-1-(2-((E)-2-cyano-3-ethoxyacryloyl)hydrazono)ethyl)
phenyl) benzenesulfonamide (6)

A mixture of 4 (3.9 g, 0.01 mol) and triethyl orthoformate (5 ml), in acetic anhydride
(5 ml) was refluxed for 8h. Acetic anhydride was evaporated, and the reaction mixture
was triturated with ethanol and filtered. The solid obtained was crystallized from
ethanol to give 6. Yield, 49%; m.p. 140-142 ºC. IR (KBr, cm-1): 3359, 3325 (2NH),
3098 (CH arom.), 2919, 2923 (CH aliph.), 1664 (C=O), 1605 (C=N), 1367, 1184
(SO2), 748 (C-Cl). 1H-NMR (DMSO-d6)δ: 1.30 [t, 3H, CH3CH2], 1.81 [s, 3H, CH3],

PT
4.1 [q, 2H, CH2], 7.08-8.08 [m, 8H, Ar-H], 7.69 [s, 1H, SO2NH exchangeable with
D2O], 8.37 [s, 1H, CH], 10.63 [s, 1H, NH exchangeable with D2O]. 13C-NMR

RI
(DMSO-d6): 25.5 (CH2-CH3), 26.8 (CH3), 79.8 (CH2), 107.9 (C-CN), 113.5 (C≡N),
118.6, 118.6, 119.8, 129.0, 129.0, 130.0, 130.0, 130.2, 130.2, 131.0, 132.6, 138.4 (C-
phenyl), 142.3 (C=N), 144.2 (C꞊O), 163.2 (CH). MS m/z (%): 446.6 (M+) (6.4), 448.5

SC
(2.1), 90 (100). Anal. Calcd. For C20H19ClN4O4S (446.91): C, 53.75; H, 4.29; N,
12.54; Found: C, 54.11; H, 4.34; N, 12.69.

U
4.1.4.(E)-3-(2-(1-(4-(4-Chlorophenylsulfonamido)phenyl)ethylidene)hydrazinyl)-2-
AN
cyano-3-oxopropanedithioic acid (8) and (E)-4-Chloro-N-(4-(1-(2-(2-cyano-3,3-
bis(methylthio)acryloyl)hydrazono)ethyl) phenyl)benzenesulfonamide (9)

Carbon disulfide (0.76 g, 0.01 mol) was added gradually to a cold solution of 4 (3.9 g,
M

0.01 mol) in N,N-dimethylformamide (15mL) containing finely grounded potassium

hydroxide (1.0 g). The reaction mixture was stirred at room temperature for 24h, then
triturated with cold water (50 mL) and neutralized with 1N HCl. The resulting
D

precipitated solid was collected, filtered and crystallized from dioxane to give 8.
While compound 9 was obtained by the same experimental procedure described
TE

above for the synthesis of 8 except that two moles of methyl iodide (2.82 g, 0.02 mol)
were added before the reaction was left at room temperature.
EP

8; Yield, 30.1%; m.p. 130-132 ºC. IR (KBr, cm-1): 3386, 3351 (2NH), 3091 (CH
arom.), 2916, 2869 (CH aliph.), 2300 (SH), 2182 (C≡N), 1664 (C=O), 1597 (C=N),
1355, 1156 (SO2), 1310 (C=S), 762 (C-Cl). 1H-NMR (DMSO-d6)δ: 2.14 [s, 1H, SH
exchangeable with D2O], 2.24 [s, 3H, CH3], 4.16 [s, 1H, CH], 7.08-7.83 [m, 8H, Ar-
C

H], 7.66 [s, 1H, SO2NH exchangeable with D2O], 10.58 [s, H, NH exchangeable with
D2O]. 13C-NMR (DMSO-d6): 26.8 (CH3), 112.7 (C-CN), 112.7 (C≡N), 118.7, 118.7,
AC

119.8, 129.0, 129.0, 130.0, 130.0, 130.3, 130.3, 132.7, 138.3, 138.5 (C-phenyl),
142.3 (C=N), 162.7 (C꞊O), 196.9 (C=S). MS m/z (%): 466.7 (M+) (1.0), 468.5 (0.3),
90.8 (100). Anal. Calcd. For C18H15ClN4O3S3 (466.98): C, 46.30; H, 3.24; N, 12.00;
Found: C, 46.06; H, 3.10; N, 11.89.

9; Yield, 48 %; m.p. 90-92 ºC. IR (KBr, cm-1): 3365, 3234 (2NH), 3043 (CH arom.),
2925, 2873 (CH aliph.), 2177 (C≡N), 1675 (C=O), 1600 (C=N), 1356, 1138 (SO2),
744 (C-Cl). 1H-NMR (DMSO-d6)δ: 2.08 [s, 3H, CH3], 2.49 [s, 6H, 2CH3], 6.72-7.64
[m, 8H, Ar-H], 7.35 [s, 1H, SO2NH exchangeable with D2O], 10.56 [s, H, NH
exchangeable with D2O]. 13C-NMR (DMSO-d6): 26.8 (CH3), 28.3, 28.3 (2(S-CH3)),
112.7 (C-CN), 112.7 (C≡N), 118.7, 118.7, 119.8, 129.0, 129.0, 130.0, 130.0, 130.3,

13
 ACCEPTED MANUSCRIPT
130.3, 132.7, 138.3, 138.4 (C-phenyl), 142.3 (C=N), 162.7 (C꞊O), 176.9 (S-C-S). MS
m/z (%): 494.7 (M+) (11.4), 496.8 (3.2), 52.2 (100). Anal. Calcd. For C20H19ClN4O3S3
(495.04): C, 48.52; H, 3.87; N, 11.32; Found: C, 48.37; H, 3.44; N, 11.03.

4.1.5. General procedure for the preparation of compounds 10-21:

A mixture of 4 (3.9 g, 0.01 mol) and ethyl α-cyanocinnamate derivatives (0.01 mol)
namely, (E)-ethyl 2-cyano-3-(furan-2-yl)acrylate, (Z)-ethyl 2-cyano-3-phenylacrylate,

PT
(Z)-ethyl 2-cyano-3-(p-tolyl)acrylate, (2Z,4E)-ethyl 2-cyano-5-phenylpenta-2,4-
dienoate, (Z)-ethyl 2-cyano-3-(2-methoxyphenyl)acrylate, (Z)-ethyl 2-cyano-3-(4-
methoxyphenyl)acrylate, (Z)-ethyl 3-(2-chlorophenyl)-2-cyanoacrylate, (Z)-ethyl 3-

RI
(4-chlorophenyl)-2-cyanoacrylate, (Z)-ethyl 2-cyano-3-(4-
(dimethylamino)phenyl)acrylate, (Z)-ethyl 3-(benzo[d][1,3]dioxol-5-yl)-2-
cyanoacrylate, (Z)-ethyl 2-cyano-3-(3-nitrophenyl)acrylate, (Z)-ethyl 2-cyano-3-(4-

SC
nitrophenyl)acrylate in 1,4-dioxane (15 mL) containing piperidine (0.5 mL) was
refluxed for 5 h. The reaction mixture was poured onto ice/water and the formed solid
was crystallized from dioxane to give 10-21, respectively.

U
4.1.5.1.(E)-N-(4-(1-((2-amino-5-cyano-3-ethylcarboxylate-4-(furan-2-yl)-6-oxo-1,6-
AN
dihydropyridin)imino)ethyl)phenyl)-4-chlorobenzenesulfonamide (10)

Yield, 76.2 %; m.p. >300 ºC. IR (KBr, cm-1): 3364, 3243, 3225 (NH2,NH), 3094 (CH
M

arom.), 2941, 2859 (CH aliph.), 2200 (C≡N), 1703, 1656 (2 C=O), 1599 (C=N), 1330,
1189 (SO2), 758 (C-Cl). 1H-NMR (DMSO-d6)δ: 0.82 [t, 3H, CH3 ester], 2.17 [s, 3H,
CH3], 3.63 [q, 2H, CH2], 7.06-7.80 [m, 8H, Ar-H], 7.07 [t, 1H, CH-CH-CH furan],
D

7.56 [s, 1H, SO2NH exchangeable with D2O], 7.60 [m, 1H, C-CH furan], 7.72 [m, 1H,
CH-O furan] 10.73 [s, 2H, NH2 exchangeable with D2O]. 13C-NMR (DMSO-d6): 22.6
TE

(CH3 ester), 26.9 (CH3), 44.2 (CH2), 83.7 (C-C=O), 118.7, 118.7 (CH furan), 119.7
(C≡N), 128.0, 128.0 (C-phenyl), 129.0 (C-C≡N), 129.1, 130.0, 130.0, 130.1, 130.1,
130.2, 130.2, 130.3, 130.5, 134.0 (C-phenyl), 138.4, 138.7 (C-O furan), 139.2 (C-
EP

NH2), 143.5 (C꞊O), 157.5 (C=N), 165.2 (C=O ester), 174.8 (C-pyridine). MS m/z
(%): 580 (M+) (13.4), 581.8 (4.1), 194.0 (100). Anal. Calcd. For C27H22ClN5O6S
(580.01): C, 55.91; H, 3.82; N, 12.07; Found: C, 55.58; H, 3.53; N, 12.01.
C

4.1.5.2.(E)-N-(4-(1-((2-amino-5-cyano-3-ethylcarboxylate-6-oxo-4-phenyl-1,6-
AC

dihydropyridin)imino)ethyl)phenyl)-4-chlorobenzenesulfonamide (11)

Yield, 28.3 %; m.p. 255-257 ºC. IR (KBr, cm-1): 3328, 3247, 3213 (NH2,NH), 3094
(CH arom.), 2941, 2808 (CH aliph.), 2195 (C≡N), 1670, 1667 (2 C=O), 1601 (C=N),
1345, 1161 (SO2), 746 (C-Cl). 1H-NMR (DMSO-d6)δ: 0.81 [t, 3H, CH3 ester], 2.14 [s,
3H, CH3], 3.65 [q, 2H, CH2], 7.3-7.70 [m, 13H, Ar-H], 7.46 [s, 1H, SO2NH
exchangeable with D2O], 10.74 [s, 2H, NH2 exchangeable with D2O]. 13C-NMR
(DMSO-d6): 22.6 (CH3 ester), 28.9 (CH3), 44.2 (CH2), 83.8 (C-C=O), 120.6 (C-C≡N),
120.6 (C≡N), 127.6, 127.6, 127.6, 127.6, 129.1, 129.6, 129.6, 129.6, 130.0, 130.0,
130.1, 130.1, 130.2, 130.2, 130.3, 130.5, 134.0, 134.6 (C-phenyl), 134.7 (C-NH2),
147.8 (C꞊O), 157.0 (C=N), 163.7 (C=O ester), 174.8 (C-pyridine). MS m/z (%): 590.0

14
 ACCEPTED MANUSCRIPT
(M+) (1.8), 592.1 (0.6), 104 (100). Anal. Calcd. For C29H24ClN5O5S (590.05): C,
59.03; H, 4.10; N, 11.87; Found: C, 59.28; H, 4.43; N, 12.05.

4.1.5.3.(E)-N-(4-(1-((2-amino-5-cyano-3-ethylcarboxylate-6-oxo-4-(p-tolyl)-1,6-
dihydropyridin)imino)ethyl)phenyl)-4-chlorobenzenesulfonamide (12)

Yield, 32.5 %; m.p. 263-265 ºC. IR (KBr, cm-1): 3327, 3228, 3213 (NH2,NH), 3086

PT
(CH arom.), 2945, 2860 (CH aliph.), 2203 (C≡N), 1673, 1667 (2 C=O), 1607 (C=N),
1340, 1160 (SO2), 740 (C-Cl). 1H-NMR (DMSO-d6)δ: 0.82 [t, 3H, CH3 ester], 1.26 [s,
1H, CH3 tolyl], 1.56 [s, 3H, CH3], 3.68 [q, 2H, CH2], 6.91-7.77 [m, 12H, Ar-H], 7.48

RI
[s, 1H, SO2NH exchangeable with D2O], 10.69 [s, 2H, NH2 exchangeable with D2O].
13
C-NMR (DMSO-d6): 21.4 (CH3 ester), 22.5 (CH3), 29.1 (CH3 p-tolyl), 44.2 (CH2),
83.6 (C-C=O), 120.8 (C-C≡N), 120.8 (C≡N), 128.2, 128.2, 128.7, 129.2, 129.2, 129.6,

SC
129.6, 129.6, 129.6, 130.0, 130.0, 130,0, 130.0, 130.1, 130.3, 130.5 131.7, 134.6 (C-
phenyl), 138.5 (C-NH2), 147.8 (C꞊O), 157.1 (C=N), 163.7 (C=O ester), 175.0 (C-
pyridine). MS m/z (%): 603.8 (M+) (9.4), 605.7 (3.1), 92.2 (100). Anal. Calcd. For

U
C30H26ClN5O5S (604.08): C, 59.65; H, 4.34; N, 11.59; Found: C, 59.28; H, 4.23; N,
11.55.
AN
4.1.5.4.(E)-N-(4-(1-((2-amino-5-cyano-3-ethylcarboxylate-6-oxo-4-((E)-styryl)-1,6-
dihydropyridin)imino)ethyl)phenyl)-4-chlorobenzenesulfonamide (13)
M

Yield, 53.8 %; m.p. 145-147 ºC. IR (KBr, cm-1): 3320, 3287, 3233 (NH2,NH), 3054
(CH arom.), 2939, 2856 (CH aliph.), 2334 (C≡N), 1738, 1687 (2 C=O), 1602 (C=N),
1348, 1169 (SO2), 756 (C-Cl). 1H-NMR (DMSO-d6)δ: 1.05 [t, 3H, CH3 ester], 2.16 [s,
D

3H, CH3], 3.74 [q, 2H, CH2], 7.02, 7.04 [2d, 2H, CH=CH], 7.30-7.77 [m, 13H, Ar-H],
7.43 [s, 1H, SO2NH exchangeable with D2O], 10.69 [s, 2H, NH2 exchangeable with
TE

D2O]. 13C-NMR (DMSO-d6): 22.6 (CH3 ester), 28.9 (CH3), 44.2 (CH2), 83.8 (C-
C=O), 120.6 (C-C≡N), 125.4 (C≡N), 127.6, 127.6 (C-phenyl), 127.8 (CH2 enol),
127.9, 128.0, 128.5, 128.5, 129.1, 129.1, 129.6, 129.6, 130.0, 130.0, 130.1, 130.1 (C-
EP

phenyl), 130.2 (CH2 enol), 130.3, 130.5, 134.0, 134.6 (C-phenyl), 134.7 (C-NH2),
147.8 (C꞊O), 157.0 (C=N), 163.7 (C=O ester), 174.8 (C-pyridine). MS m/z (%): 615.5
(M+) (13.4), 617.8 (4.9), 97.7 (100). Anal. Calcd. For C31H26ClN5O5S (616.09): C,
60.43; H, 4.25; N, 11.37; Found: C, 60.28; H, 4.23; N, 11.15.
C

4.1.5.5.(E)-N-(4-(1-((2-amino-5-cyano-3-ethylcarboxylate-4-(2-methoxyphenyl)-6-
AC

oxo-1,6-dihydropyridin)imino)ethyl)phenyl)-4-chlorobenzenesulfonamide (14)

Yield, 29.1 %; m.p. 161-163 ºC. IR (KBr, cm-1): 3381, 3234, 3219 (NH2,NH), 3094
(CH arom.), 2942, 2856 (CH aliph.), 2216 (C≡N), 1732, 1657 (2C=O), 1600 (C=N),
1345, 1132 (SO2), 758 (C-Cl). 1H-NMR (DMSO-d6)δ: 1.03 [t, 3H, CH3 ester], 2.06 [s,
3H, CH3], 3.60 [s, 3H, OCH3], 3.66 [q, 2H, CH2], 7.02-7.74 [m, 12H, Ar-H], 7.58 [s,
1H, SO2NH exchangeable with D2O], 10.69 [s, 2H, NH2 exchangeable with D2O].
13
C-NMR (DMSO-d6): 22.6 (CH3 ester), 25.9 (CH3), 44.8 (OCH3), 48.2 (CH2), 83.8
(C-C=O), 112.9 (C-phenyl), 113.7 (C-C≡N), 118.8 (C≡N), 127.6, 127.6, 128.0, 128.5,
129.1, 129.6, 129.6, 129.8, 130.0, 130.0, 130.1, 130.1, 130.2, 130.3, 130.5, 134.6 (C-
phenyl), 134.7 (C-NH2), 140.0 (C- phenyl), 147.8 (C꞊O), 157.0 (C=N), 163.7 (C=O

15
 ACCEPTED MANUSCRIPT
ester), 174.8 (C-pyridine). MS m/z (%): 619.8 (M+) (8.2), 621.5 (2.8), 90 (100). Anal.
Calcd. For C30H26ClN5O6S (620.08): C, 58.11; H, 4.23; N, 11.29; Found: C, 58.38; H,
4.45; N, 11.54.

4.1.5.6.(E)-N-(4-(1-((2-amino-5-cyano-3-ethylcarboxylate-4-(4-methoxyphenyl)-6-
oxo-1,6-dihydropyridin)imino)ethyl)phenyl)-4-chlorobenzenesulfonamide (15)

Yield, 83 %; m.p. 161-163 ºC. IR (KBr, cm-1): 3328, 3294, 3203 (NH2,NH), 3094

PT
(CH arom.), 2934, 2854 (CH aliph.), 2203 (C≡N), 1792, 1677 (2 C=O), 1602 (C=N),
1345, 1161 (SO2), 753 (C-Cl). 1H-NMR (DMSO-d6)δ: 1.03 [t, 3H, CH3 ester], 2.14 [s,
3H, CH3], 3.52 [s, 3H, OCH3], 3.66 [q, 2H, CH2], 6.91-8.12 [m, 13H, Ar-H], 7.44 [s,

RI
1H, SO2NH exchangeable with D2O], 10.69 [s, 2H, NH2 exchangeable with D2O].
13
C-NMR (DMSO-d6): 22.6 (CH3 ester), 25.3 (CH3), 44.6 (OCH3), 48.0 (CH2), 83.5
(C-C=O), 112.9, 112.9 (C-phenyl), 113.7 (C-C≡N), 118.8 (C≡N), 126.5, 126.5, 126.7,

SC
127.8, 128.8, 128.8, 131.2, 131.2, 132.1, 132.1, 132.6, 132.6, 133.3, 133.5, 134.6 (C-
phenyl), 134.7 (C-NH2), 140.0 (C- phenyl), 147.9 (C꞊O), 157.0 (C=N), 162.3 (C=O
ester), 163.8 (C-pyridine). MS m/z (%): 619.5 (M+) (3.4), 621.6 (1.0), 90.7 (100).
Anal. Calcd. For C30H26ClN5O6S (620.08): C, 58.11; H, 4.23; N, 11.29; Found: C,

U
58.28; H, 4.29; N, 11.37.
AN
4.1.5.7.(E)-N-(4-(1-((2-amino-4-(2-chlorophenyl)-5-cyano-3-ethylcarboxylate-6-oxo-
1,6-dihydropyridin)imino)ethyl)phenyl)-4-chlorobenzenesulfonamide (16)

Yield, 19.4 %; m.p. 110-112 ºC. IR (KBr, cm-1): 3315, 3257, 3223 (NH2,NH), 3086
M

(CH arom.), 2934, 2855 (CH aliph.), 2206 (C≡N), 1794, 1667 (2 C=O), 1597 (C=N),
1331, 1172 (SO2), 745 (C-Cl). 1H-NMR (DMSO-d6)δ: 1.39 [t, 3H, CH3 ester], 2.15 [s,
D

3H, CH3], 3.60 [q, 2H, CH2], 6.90-8.02 [m, 12H, Ar-H], 7.44 [s, 1H, SO2NH
exchangeable with D2O], 10.73 [s, 2H, NH2 exchangeable with D2O]. 13C-NMR
TE

(DMSO-d6): 21.5 (CH3 ester), 22.1 (CH3), 43.6 (CH2), 71.5 (C-C=O), 115.3 (C-C≡N),
115.8 (C≡N), 116.4, 116.4, 126.7, 127.5, 127.9, 128.7, 128.7, 129.1, 129.1, 129.3,
129.9, 130.0, 130.0, 135.3, 135.8, 137.5, 137.8, 140.0 (C-phenyl), 152.3 (C-NH2),
160.0 (C꞊O), 163.6 (C=N), 165.3 (C=O ester), 169.8 (C-pyridine). MS m/z (%): 624.5
EP

(M+) (5.2), 626.5 (1.9), 185.2 (100). Anal. Calcd. For C29H23Cl2N5O5S (624.49): C,
55.77; H, 3.71; N, 11.21; Found: C, 55.88; H, 3.94; N, 11.37.
C

4.1.5.8.(E)-N-(4-(1-((2-amino-4-(4-chlorophenyl)-5-cyano-3-ethylcarboxylate-6-oxo-
1,6-dihydropyridin)imino)ethyl)phenyl)-4-chlorobenzenesulfonamide (17)
AC

Yield, 30.8 %; m.p. 148-150 ºC. IR (KBr, cm-1): 3346, 3250, 3220 (NH2,NH), 3076
(CH arom.), 2941, 2865 (CH aliph.), 2217 (C≡N), 1792, 1636 (2 C=O), 1598 (C=N),
1334, 1169 (SO2), 740 (C-Cl). 1H-NMR (DMSO-d6)δ: 1.23 [t, 3H, CH3 ester], 2.14 [s,
3H, CH3], 3.60 [q, 2H, CH2], 7.12-7.97 [m, 12H, Ar-H], 7.49 [s, 1H, SO2NH
exchangeable with D2O], 10.67 [s, 2H, NH2 exchangeable with D2O]. 13C-NMR
(DMSO-d6): 21.5 (CH3 ester), 22.1 (CH3), 43.6 (CH2), 71.5 (C-C=O), 115.3 (C-C≡N),
115.8 (C≡N), 116.4, 116.4, 126.7, 127.5, 127.5, 127.9, 127.9, 128.7, 128.7, 129.1,
129.1, 129.1, 129.1, 129.3, 129.9, 135.3, 135.8, 137.5 (C-phenyl), 152.3 (C-NH2),
160.0 (C꞊O), 163.6 (C=N), 165.3 (C=O ester), 169.8 (C-pyridine). MS m/z (%): 624.4
(M+) (6.4), 626.5 (2.2), 185.2 (100). Anal. Calcd. For C29H23Cl2N5O5S (624.49): C,
55.77; H, 3.71; N, 11.21; Found: C, 55.82; H, 3.91; N, 11.39.

16
 ACCEPTED MANUSCRIPT

4.1.5.9.(E)-N-(4-(1-((2-amino-5-cyano-4-(4-(dimethylamino)phenyl)-3-
ethylcarboxylate-6-oxo-1,6-dihydropyridin)imino)ethyl)phenyl)-4-
chlorobenzenesulfonamide (18)

Yield, 38 %; m.p. 258-260 ºC. IR (KBr, cm-1): 3300, 3206, 3169 (NH2,NH), 3090
(CH arom.), 2934, 2858 (CH aliph.), 2207 (C≡N), 1708, 1687 (2 C=O), 1595 (C=N),
1324, 1188 (SO2), 753 (C-Cl). 1H-NMR (DMSO-d6)δ: 1.50 [t, 3H, CH3 ester], 2.22 [s,
3H, CH3], 3.06 [s, 6H, N(CH3)2], 3.63 [q, 2H, CH2], 6.50-8.00 [m, 12H, Ar-H], 7.99

PT
[s, 1H, SO2NH exchangeable with D2O], 10.66 [s, 2H, NH2 exchangeable with D2O].
13
C-NMR (DMSO-d6): 22.6 (CH3 ester), 30.1 (CH3), 42.7, 42.7 (N(CH3)2), 44.2
(CH2), 83.8 (C-C=O), 116.4, 116.4 (C-phenyl), 119.2 (C-C≡N), 119.2 (C≡N), 125.1,

RI
125.1, 127.6, 128.3, 128.3, 128.3, 128.6, 128.6, 129.6, 129.6, 130.2, 130.2, 130.3,
133.0, 134.0 (C-phenyl), 134.3 (C-N(CH3)2), 134.7 (C-NH2), 147.1 (C꞊O), 157.0
(C=N), 163.7 (C=O ester), 174.8 (C-pyridine). MS m/z (%): 632.8 (M+) (3.1), 634.5

SC
(1.2), 90 (100). Anal. Calcd. For C31H29ClN6O5S (633.12): C, 58.81; H, 4.62; N,
13.27; Found: C, 58.99; H, 4.79; N, 13.39.

4.1.5.10.(E)-N-(4-(1-((2-amino-4-(benzo[d][1,3]dioxol-5-yl)-5-cyano-3-

U
ethylcarboxylate-6-oxo-1,6-dihydropyridin)imino)ethyl)phenyl)-4-
AN
chlorobenzenesulfonamide (19)

Yield, 42.9 %; m.p. >300 ºC. IR (KBr, cm-1): 3340, 3258, 3210 (NH2,NH), 3088 (CH
arom.), 2958, 2895 (CH aliph.), 2202 (C≡N), 1798, 1648 (2 C=O), 1556 (C=N), 1364,
M

1154 (SO2), 748 (C-Cl). 1H-NMR (DMSO-d6)δ: 1.51 [t, 3H, CH3 ester], 2.21 [s, 3H,
CH3], 3.67 [q, 2H, CH2 ester], 6.09 [s, 2H, CH2], 6.80-7.70 [m, 13H, Ar-H], 7.66 [s,
1H, SO2NH exchangeable with D2O], 10.67 [s, 2H, NH2 exchangeable with D2O].
D

13
C-NMR (DMSO-d6): 22.0 (CH3 ester), 22.7 (CH3), 44.1 (CH2 ester), 83.8 (C-C=O),
93.8 (CH2), 101.5, 101.5 (C-phenyl), 107.7 (C-C≡N), 110.5 (C≡N), 120.7, 120.7,
TE

120.7, 123.6, 123.6, 123.6, 123.6, 128.2, 128.2, 128.2, 128.2, 130.0, 130.2, 130.3,
130.5, 134.0 (C-phenyl), 146.6 (C-NH2), 147.8 (C꞊O), 156.7 (C=N), 163.7 (C=O
ester), 174.7 (C-pyridine). MS m/z (%): 633.9 (M+) (11.4), 635.5 (3.2), 90.7 (100).
Anal. Calcd. For C30H24ClN5O7S (634.06): C, 56.83; H, 3.82; N, 11.05; Found: C,
EP

56.96; H, 4.00; N, 11.30.

4.1.5.11.(E)-N-(4-(1-((2-amino-5-cyano-3-ethylcarboxylate-4-(3-nitrophenyl)-6-oxo-
C

1,6-dihydropyridin)imino)ethyl)phenyl)-4-chlorobenzenesulfonamide (20)
AC

Yield, 34.4 %; m.p. 130-132 ºC. IR (KBr, cm-1): 3372, 3259, 3233 (NH2,NH), 3086
(CH arom.), 2932, 2852 (CH aliph.), 2200 (C≡N), 1790, 1657 (2 C=O), 1607 (C=N),
1507, 1310 (NO2), 1341, 1152 (SO2), 742 (C-Cl). 1H-NMR (DMSO-d6)δ: 1.23 [t, 3H,
CH3 ester], 2.16 [s, 3H, CH3], 3.61 [q, 2H, CH2], 6.92-8.30 [m, 12H, Ar-H], 7.54 [s,
1H, SO2NH exchangeable with D2O], 10.69 [s, 2H, NH2 exchangeable with D2O].
13
C-NMR (DMSO-d6): 22.6 (CH3 ester), 26.7 (CH3), 44.2 (CH2), 83.8 (C-C=O),
110.6 (C-C≡N), 110.6 (C≡N), 124.0, 124.0, 127.6, 127.8, 128.1, 128.9, 128.9, 129.0,
129.0, 129.9, 130.0, 130.0, 130.1, 130.2, 130.3, 130.5, 134.0 (C-phenyl), 134.2 (C-
NO2), 134.7 (C-NH2), 147.8 (C꞊O), 157.0 (C=N), 163.7 (C=O ester), 174.8 (C-
pyridine). MS m/z (%): 634.5 (M+) (5.9), 636.7 (1.8), 120.2 (100). Anal. Calcd. For
C29H23ClN6O7S (635.05): C, 54.85; H, 3.65; N, 13.23; Found: C, 54.99; H, 3.82; N,
13.41.

17
 ACCEPTED MANUSCRIPT

4.1.5.12.(E)-N-(4-(1-((2-amino-5-cyano-3-ethylcarboxylate-4-(4-nitrophenyl)-6-oxo-
1,6-dihydropyridin)imino)ethyl)phenyl)-4-chlorobenzenesulfonamide (21)

Yield, 94.5 %; m.p. 141-143 ºC. IR (KBr, cm-1): 3360, 3234, 3213 (NH2,NH), 3096
(CH arom.), 2934, 2858 (CH aliph.), 2211 (C≡N), 1780, 1650 (2 C=O), 1600 (C=N),
1500, 1318 (NO2), 1349, 1142 (SO2), 740 (C-Cl). 1H-NMR (DMSO-d6)δ: 1.21 [t, 3H,
CH3 ester], 2.10 [s, 3H, CH3], 3.84 [q, 2H, CH2], 6.94-8.32 [m, 12H, Ar-H], 7.77 [s,
1H, SO2NH exchangeable with D2O], 10.68 [s, 2H, NH2 exchangeable with D2O].

PT
13
C-NMR (DMSO-d6): 22.6 (CH3 ester), 26.7 (CH3), 44.2 (CH2), 83.8 (C-C=O),
110.6 (C-C≡N), 110.6 (C≡N), 124.0, 124.0, 127.6, 127.6, 128.1, 128.9, 128.9, 129.0,
129.0, 129.9, 129.9, 130.2, 130.2, 130.3, 130.5, 134.0, 134.0 (C-phenyl), 134.2 (C-

RI
NO2), 134.7 (C-NH2), 147.8 (C꞊O), 157.0 (C=N), 163.7 (C=O ester), 174.8 (C-
pyridine). MS m/z (%): 634.6 (M+) (7.2), 636.5 (2.4), 58.4 (100). Anal. Calcd. For
C29H23ClN6O7S (635.05): C, 54.85; H, 3.65; N, 13.23; Found: C, 55.01; H, 3.71; N,

SC
13.47.

4.2. In-vitro anticancer evaluation against human tumor liver cancer

U
(HepG2)
AN
The in-vitro anticancer activity was measured for seventeen new compounds
on liver human tumor cell line (HepG2) using the Sulfo-Rhodamine-B stain (SRB)
assay. The in-vitro anticancer screening was done by the pharmacology unit at the
M

National Cancer Institute, Cairo University.

The sulfo-rhodamine B (SRB) assay which was developed in 1990 [47], remains one
D

of the most widely used methods for in-vitro cytotoxic screening. The assay relies on the
ability of SRB to bind to protein components of cells that have been fixed to tissue-culture
TE

plates by trichloroacetic acid (TCA). SRB is a bright-pink aminoxanthene dye with two
sulfonic groups that bind to basic amino-acid residues under mild acidic conditions, and
dissociate under basic conditions. The amount of dye extracted from stained cells is directly
proportional to the cell mass [48]. Cells were plated in 96-multiwell plate (104 cells/ well) for
EP

24 hrs before treatment with the compounds to allow attachment of the cells to the wall of the
plate. Test compounds were dissolved in dimethylsulfoxide (DMSO) and diluted with saline
to the appropriate volume. Different concentrations of the compounds under test (12.5, 25, 50
C

and 100 µM) were added to the cell monolayer. Triplicate wells were prepared for each
individual dose. Monolayer cells were incubated with the compounds for 48 hrs at 37ºC and in
AC

atmosphere of 5% CO2. After 48 hrs, cells were fixed, washed and stained for 30 min. with
0.4% (wt/ vol) SRB dissolved in 1% acetic acid. Unbounded dye was removed by four
washes with 1% acetic acid, and attached stain was recovered with Tris-EDTA buffer. Color
intensity was measured in an enzyme linked immunosorbent assay (ELISA) reader. The
relation between surviving fraction and drug concentration is plotted to get the survival curve
of each tumor cell line after the specified time. The concentration required for 50%
inhibition of cell viability (IC50) was calculated and compared with the reference drug
doxorubicin and the results are given in table 1.

Doxorubicin (CAS, 25316-40-9), the reference drug used in this study is a

drug used in cancer chemotherapy. It is an anthracycline antibiotic, it works by

18
 ACCEPTED MANUSCRIPT
intercalating DNA and inhibition of macromolecular biosynthesis. It is commonly
used in the treatment of a wide range of cancers as in acute leukemia’s, Hodgkin’s
disease, and other lymphomas [49].

4.3. Radisensitizing evaluation

Irradiation was performed at the National Center for Radiation Research and
Technology, Atomic Energy Authority, using Gamma cell-40 (137Cs) source. The
most active compounds 4, 10 and 12 were selected to be re-evaluated for their in-vitro

PT
cytotoxic activity in combination with γ-irradiation. Cells were plated in 96-multiwell
plate (104cells/well) for 24 h. before γ-irradiation with a single dose of 8 Gy. Cells
were incubated for 48 h. at 37 ˚C in atmosphere of 5% CO2. After 48 h., cells were

RI
fixed, washed and stained with 0.4% (wt/vol) SRB dissolved in 1% acetic acid, for 30
minutes. Excess unbound dye was removed by four washes with 1% acetic acid and

SC
attached stain was recovered with Tris–EDTA buffer. Color intensity was measured
by an ELISA reader at a wave length of 570 nm. In another multiwell plate, cells were
incubated with compounds 4, 10 and 12 in molar concentrations of 12.5, 25, 50 and

U
100 µM. After 2 h., cells were subjected to a single dose of γ-radiation at a dose level
of 8 Gy with a dose rate of 0.758 rad/sec for 17.73 min, then the cytotoxicity was
AN
measured 48h. after irradiation. The surviving fractions were measured using the
above mentioned procedures by ELISA reader. The surviving fractions were
expressed as mean values ± standard error. The results were analyzed using 1-way
M

ANOVA test and given in Table 2 .

4.4. Molecular modeling and docking

D

The molecular model of the new sulfonamide derivatives was built using
TE

standard bond lengths and angles, with the MOE software suite 2007.09. Following
geometry optimization, a systematic conformational search was carried out to an RMS
gradient of 0.01Å with energy minimization of the resultant conformations employing
the ConfSearch module implemented in MOE. All molecular mechanics computations
EP

were performed with the Merck Force Field (MMFF94s). The experimental
crystallographic structures of CA IX complex was retrieved from the Protein
DataBank (PDB ID: 4BCW). Missing hydrogens were added to the enzyme and
C

partial charges were calculated. After removing the co-crystallized inhibitor,

validation followed by docking of the compounds were carried out using MOE
AC

software suite 2007.09. The target protein was kept rigid, while the ligands were left
free to explore the conformational space inside the enzyme cavity; 100 separate
docking simulations were run using default parameters and the conformations were
chosen based on the combination of S score data, E conformation and appropriate
fitting with the relevant amino acids in the binding pocket.

References:
[1] S.K. Kim, Handbook of Anticancer Drugs from Marine Origin, Springer
International Publishing, Switzerland, 2015.

19
 ACCEPTED MANUSCRIPT

[2] P. Heffeter, M.A. Jakupec, W. Korner, S. Wild, N.G. von Keyserlingk, L. Elbling,
H. Zorbas, A. Korynevska, S. Knasmuller, H. Sutterluty, M. Micksche, B.K. Keppler,
W. Berger, Anticancer activity of the lanthanum compound [tris(1,10-
phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24). Biochem. Pharmacol.
71 (2006) 426-440.

[3] M.S. Bashandy, M.S. Alsaid, R.K. Arafa, and M.M. Ghorab, Design, synthesis
and molecular docking of novel N,N-dimethylbenzenesulfonamide derivatives as

PT
potential antiproliferative agents J Enzyme Inhib Med Chem, 29(5) (2014) 619–627

[4] M.M. Ghorab, M. Ceruso, M.S. Alsaid, Y.M. Nissan, R.K. Arafa, C.T. Supuran,

RI
Novel sulfonamides bearing pyrrole and pyrrolopyrimidine moieties as carbonic
anhydrase inhibitors: Synthesis, cytotoxic activity and molecular modeling European
J. Med. Chem. 87 (2014) 186-196.

SC
[5] J. Drews, Drug discovery: a historical perspective. Science 287 (2000) 1960-1964.

U
[6] C.T. Supuran, A. Casini, A. Mastrolorenzo, A. Scozzafava, COX-2 selective
inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides
AN
belonging to this class of pharmacological agents. Mini-Rev. Med. Chem. 4 (2004)
625-632.

[7] F. Abbate, A. Casini, T. Owa, A. Scozzafava, C.T. Supuran, Carbonic anhydrase

M

inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic

isozymes I and II, and transmembrane, tumor-associated isozyme IX, Bioorg. Med.
Chem. Lett. 14 (2004) 217-223.
D

[8] K. L. Manasa, E7010: Investigational anticancer agents targeting the microtubules.

TE

IJPSR 6(9) (2015) 3713-3725.

[9] M. Mojzych, M. Ceruso, A. Bielawska, K. Bielawski, E. Fornal, C.T. Supuran,

EP

New pyrazolo[4,3-e][1,2,4]triazine sulfonamides as carbonic anhydrase inhibitors.

Bioorg. Med. Chem. 23 (2015) 3674–3680
C

[10] P. Ebbesen, E.O. Pettersen, T.A. Gorr, G. Jobst, K. Williams, J. Kienninger,

R.H. Wenger, S. Pastorekova, L. Dubois, P. Lambin, B.G. Wouters, C.T. Supuran, L.
AC

Poellinger, P. Ratcliffe, A. Kanopka, A. Gorlach, M. Gasmann, A.L. Harris, P.

Maxwell, A. Scozzafava. Taking advantage of tumor cell adaptations to hypoxia for
developing new tumor markers and treatment strategies. J.Enzyme Inhib. Med. Chem.
24 (2009) 1-39.
[11] J. Pastorek, S. Pastorekova, Molecular Mechanisms Regulating Expression and
Function of Cancer-Associated Carbonic Anhydrase IX, The tumor
microenvironment, chapter 4 (2010) 59-90.
[12] M. Stubbs, P.M. McSheehy, J.R. Griffiths, C.L. Bashford, Causes and
consequences of tumour acidity and implications for treatment. Mol Med Today 6
(2000) 15–19.

20
 ACCEPTED MANUSCRIPT
[13] J. Pouyssegur, F. Dayan, N.M. Mazure, Hypoxia signalling in cancer and
approaches to enforce tumour regression. Nature 441 (2006) 437–443.

[14] E. Svastova, A. Hulikova, M. Rafajova, M. Zat’ovicova, A. Gibadulinova, A.

Casini, A. Cecchi, A. Scozzafava, C.T. Supuran, J. Pastorek, S. Pastorekova, Hypoxia
activates the capacity of tumor-associated carbonic anhydrase IX to acidify
extracellular pH. FEBS Lett 577 (2004) 439–445.

[15] P. Swietach, S. Wigfield, C.T. Supuran, A.L. Harris, R.D.Vaughan-Jones,

PT
Cancer-associated, hypoxia-inducible carbonic anhydrase IX facilitates CO2 diffusion.
BJU Int 101 Suppl 4 (2008) 22–4.

RI
[16] S.V. Kozin, P. Shkarin, L.E. Gerweck, The cell transmembrane pH gradient in
tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res 61
(2001) 4740–4743.

SC
[17] V. Vukovic, I.F. Tannock, Influence of low pH on cytotoxicity of paclitaxel,
mitoxantrone and topotecan. Br J Cancer 75 (1997) 1167–1172.

U
[18] N. Raghunand, R.A. Gatenby, R.J. Gillies, Microenvironmental and cellular
consequences of altered blood flow in tumours. Br J Radiol 76 Spec No 1 (2003)
AN
S11–S22.

[19] A. Masunari, L.C. Tavares, A new class of nifuroxazide analogues: Synthesis of

M

5-nitrothiophene derivatives with antimicrobial activity against multidrug-resistant

Staphylococcus aureus. Bioorg. Med. Chem. 15 (2007) 4229–4236.
D

[20] R. Kaplanek, M. Jakubek, J. Rak, Z. Kejik, M. Havlik, B. Dolensky, I. Frydrych,

TE

M. Hajduch, M. Kolar, K. Bogdanova, J. Kralova, P. Dzubak, V. Kral, Caffeine

hydrazones as anticancer agents with pronounced selectivity toward T-lymphoblastic
leukaemia cells. Bioorg. Chem. 60 (2015) 19–29.
EP

[21] J.X. Deng, T. Sanchez, L.Q. Al-Mawsawi, R. Dayam, R.A. Yunes, A. Garofalo,
M.B. Bolger, N. Neamati, Discovery of structurally diverse HIV-1 integrase inhibitors
based on a chalcone pharmacophore. Bioorg. Med. Chem. 15 (2007) 4985–5002.
C
AC

[22] P. Vicini, M. Incerti, I.A. Doytchinova, P. La Colla, B. Busonera, R. Loddo,

Synthesis and antiproliferative activity of benzo[d]isothiazole hydrazones. European
J. Med. Chem. 41 (2006) 624-632.

[23] N. Terzioglu, A. Gürsoy, Synthesis and anticancer evaluation of some new

hydrazone derivatives of 2,6-dimethylimidazo[2,1-b][1,3,4]thiadiazole-5-
carbohydrazide. Eur. J. Med. Chem. 38 (2003) 781-786.

21
 ACCEPTED MANUSCRIPT
[24] A.H. Abadi, A.A.H. Eissa, G.S. Hassan, Synthesis of novel 1, 3, 4-trisubstituted
pyrazole derivatives and their evaluation as antitumor and antiangiogenic agents.
Chem. Pharm. Bullet. 51 (2003) 838-844.

[25] D. Kumar, N.M. Kumar, S. Ghosh, K. Shah, Novel bis(indolyl)hydrazide-

hydrazones as potent cytotoxic agents. Bioorg. Med. Chem. Lett. 22 (2012) 212-215.

[26] A.G. Nerkar, A.K. Saxena, S.A. Ghone, A.K. Thaker, In Silico Screening,
Synthesis and In Vitro Evaluation of Some Quinazolinone and Pyridine Derivatives as

PT
Dihydrofolate Reductase Inhibitors for Anticancer Activity. Eur. J. Chem. 6 (2009)
S97-S102.

RI
[27] D. Petch, R.J. Anderson, A. Cunningham, S.E. George, D.E. Hibbs, R. Liu, S.P.
Mackay, A. Paul, D.A.P. Small, P.W. Groundwater, Bioorg. Med. Chem. 20 (2012)
5901–5914.

SC
[28] H. S. Ibrahim, S.M. Abou-seri, N.S.M. Ismail, M.M. Elaasser, M. H. Aly, H.A.
Abdel-Aziz, Bis-isatin hydrazones with novel linkers: Synthesis and biological

U
evaluation as cytotoxic agents. Eur. J. Med. Chem. 108 (2016) 415-422.
AN
[29] M. Niewerth, D. Kunze, M. Seibold, M. Schalle, H.C. Korting, B. Hube.
Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes
encoding virulence factors, iron metabolism proteins, and drug resistance factors,
Antimicrob. Agent and Chemother. 47(6) (2003) 1805-1817.
M

[30] Li. Qun, L.A.Mitscher, L.L.Shen, The 2‐pyridone antibacterial agents: bacterial
topoisomerase inhibitors, Med. Res. Rev.20(4) (2000) 231-293.
D

[31] J.B. Pierce, Z.S. Ariyan, G.S. Ovenden, Preparation and antiinflammatory
TE

activity of 2-and 4-pyridones. J. Med. Chem. 25(2) (1982) 131-136.

[32] M.M.F. Ismail, Y.A. Ammar, H.S.A. El-Zahaby, S.I. Eisa, S. El-Sayed Barakat,
Synthesis of Novel 1‐Pyrazolylpyridin‐2‐ones as Potential Anti‐Inflammatory and
EP

Analgesic Agents, Arch. Pharm. Chem. Life Sci. 340 (9) (2007) 476-482.

[33] M. Isaka, M. Tanticharoen, Structures of Cordypyridones AD, Antimalarial N-

C

Hydroxy-and N-Methoxy-2-pyridones from the Insect Pathogenic Fungus Cordyceps

n ipponica, J. Org. Chem. 66 (14) (2001) 4803-4808.
AC

[34] H. Khanam, Shamsuzzaman, Bioactive Benzofuran derivatives: A review, Eur. J.

Med. Chem. 97 (2015) 483-504.
[35] Y. Uto, Recent progress in the discovery and development of stearoyl CoA
desaturase inhibitors, Chemistry and Physics of Lipids (2015) under press.

[36] R.C. Pandey, M.W. Toussaint, R.M. Stroshane, C.C.Kalita, A.A. Aszalas, A.L.
Gawetson, T.T. Wei, K.M. Byrne, R.F. Geoghegan Jr., R.J. hite, Fredericamycin A a
new antitumor antibiotic. I. Production, isolation and physicochemical properties, J.
Antibiot. 34 (1981) 1389-1401.

22
 ACCEPTED MANUSCRIPT
[37] T. Baladi, V. Abet, S. Piguel, State-of-the-art of small molecule inhibitors of the
TAM family: The point of view of the chemist, Eur. J. Med. Chem. 105 (2015) 220-
237.

[38] Y.C. Mayur, G.J. Peters, V.V. Prasad, C. Lemo, N.K. Sathish, Design of new
drug molecules to be used in reversing multidrug resistance in cancer cells, Curr.
Cancer. Drug. Targets. 9 (2009) 298-306.

[39] V.R. Solomon, C. Hu, H. Lee, Hybrid pharmacophore design and synthesis of

PT
isatin-benzothiazole analogs for their anti-breast cancer activity, Bioorg. Med. Chem.
17(21) (2009) 7585-7592.

RI
[40] M.M. Ghorab, F.A. Ragab, H.I. Heiba, M.G. El-Gazzar, M.G. El-Gazzar,
Synthesis, in-vitro anticancer screening and radiosensitizing evaluation of some new
N-(quinoxalin-2-yl)benzenesulfonamide derivatives, Arzneim.-forsch. 62(1) (2012)

SC
46-52.

[41] M.M. Ghorab, F.A. Ragab, H.I. Heiba, M.G. El-Gazzar, M.G. El-Gazzar,
Synthesis, in vitro anticancer screening and radiosensitizing evaluation of some new

U
4-[3-(substituted)thioureido]-N-(quinoxalin-2-yl)-benzenesulfonamide derivatives,
Acta. Pharm. 61(4) (2011) 415-25.
AN
[42] M.M. Ghorab, F.A. Ragab, H.I. Heiba, H. Abou Youssef, M.G. El-Gazzar,
Synthesis of novel pyrazole and pyrimidine derivatives bearing sulfonamide moiety as
M

antitumor and radiosensitizing agents, Med. Chem. Res. 21 (2012) 1376-1383.

[43] H.M. Aly, M.G. El-Gazzar, Novel Pyrazole Derivatives as Anticancer and
D

Radiosensitizing Agents, Arzneim.-forsch. 62 (2012) 105-112.

TE

[44] Z. Cheng-Chu, L. Xue-Mei, Y. Hong, Z. Ru-Gang, Design and Synthesis of p/m-

[p-(un)Substituted Phenylsulfonamido] phenyl β-Diketo Acids and Quinoxalone
Derivatives, Chin. J. Chem. 25 (2007) 1174—1182.
EP

[45] C.T. Supuran, Inhibition of carbonic anhydrase IX as a novel anticancer

mechanism. World J Clin Oncol 3 (2012) 98–103.
C

[46] K. Tars, D. Vullo, A. Kazaks, Sulfocoumarins (1,2-benzoxathiine- 2,2-dioxides):

a class of potent and isoform-selective inhibitors of tumor-associated carbonic
AC

anhydrases. J Med Chem 56 (2013) 293–300.

[47] S.P. Storeng, R. Scudiero, D. Monks, A. McMahon, J. Vistica, D. Warren, J.T.

Bokesch, H. Kenney, S. Boyd, M.R, New colorimetric cytotoxicity assay for
anticancer-drug screening, J. Natl. Cancer Inst. 82 (1990) 1107-1112.

[48] L.V. Rubinstein, R.H. Shoemaker, K.D. Paull, R.M. Simon, S. Tosini, P. Skehan,
D.A. Scudiero, A. Monks, M.R. Boyd, Comparison of in vitro anticancer-drug-
screening data generated with a tetrazolium assay vs. a protein assay against a diverse
panel of human tumor cell lines. J. Natl. Cancer Inst. 82 (1990) 1113-1118.

23
 ACCEPTED MANUSCRIPT
[49] F.A. Fornari, J.K. Randolph, J.C. Yalowich, M.K. Ritke, D.A. Gewirtz,
Interference by Doxorubicin with DNA unwinding in MCF-7 breast tumor cells, Mol.
Pharmacol. 45 (1994) 649–656.

List of captions:

Scheme 1. Synthesis of the hydrazone derivatives 4-9

PT
Scheme 2. Synthesis of the pyridone derivatives 10-21

Table 1: In vitro anticancer screening of the synthesized compounds against human

RI
liver cell line (HepG2).

SC
Table 2: In vitro anticancer screening of compounds 4, 10 and 12 against human liver

cell line (HepG2) in combination with radiation.

U
Figure 1. Docking validation for the re-docked ligand (red) compared to the co-
AN
crystallized ligand (blue) in the active site of CA IX (S=-14.04 Kcal mol-1).

Figure 2. 3D Docking of sulfonamide derivative 4 (red) (S=-10.92 Kcal mol-1)

M

compared to the co-crystallized ligand (blue) in the active site of CA IX.

D

Figure 3. 2D ligand interaction of sulfonamide derivative 4 with active site amino

TE

acids of CA IX.

Figure 4. 2D ligand interaction of sulfonamide derivative 10 with active site amino

EP

acids of CA IX.
C

Figure 5. 2D ligand interaction of sulfonamide derivative 12 with active site amino

AC

acids of CA IX.

24
 ACCEPTED MANUSCRIPT
Research Highlights
• Novel sulfonamide derivatives bearing a hydrazone moiety were synthesized.
• Novel sulfonamide derivatives bearing a pyridone moiety were synthesized.
• In-vitro anticancer evaluation on HepG2 cell line.
• Radiosensitizer evaluation for the most potent compounds.

PT
RI
U SC
AN
M
D
TE
C EP
AC